Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BioVaxys Technology Corp. (C:BIOV)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for BIOV within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 19, 2022 23:17 ET
BIOVAXYS CLOSES FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT
VANCOUVER, BC, Sept. 19, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of its previously announced non-brokered private placement (the "Private Placement"). Pursuant to the Final Tranche of the Private Placement, the Company has issued 1,350,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $135,000. Including the first tranche of the Private Placement which completed on August 26, 2022, the Company raised total aggregate gross proceed
Read full article
Sep 08, 2022 08:00 ET
BioVaxys Announces New Chief Financial Officer
VANCOUVER, BC, Sept. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer. Mr. Loverock is replacing Mr. Lachlan McLeod, who has been the acting CFO following the transition from Lions Bay Mining Inc. to BioVaxys in October 2020.  Mr. McLeod will be resuming his full-time duties with Fehr & Associates CPA.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
3.28
--
--
Price to Sales - TTM
--
4.71
4.54
Price to Book - most recent quarter
1.68
2.10
1.83
Price to Cash Flow per share - TTM
--
2.78
10.24
Price to Free Cash Flow per share - TTM
--
2.46
15.03
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 15, 20224,606-46,072
Aug 31, 202250,678-6,013
Aug 15, 202256,69152,840
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BioVaxys Technology Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

See business summary

 

Twitter

Search (past week) for $BIOV.CA

  • No tweets found